Placebo News and Research

RSS

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new study published in The Lancet Infectious Diseases.

30 Nov 2022

Study examines cannabidiol's effect on simulated driving

Researchers use simulated driving performance to investigate whether drowsiness induced by the medical use of cannabidiol had an impact on safe driving.

29 Nov 2022

How does quinoa affect the gut microbiome of men?

Although a high intake of whole grain foods reduces the risk of cardiometabolic diseases, obesity, type 2 diabetes, and certain types of cancers, the underlying mechanism behind this occurrence is unclear. Whole grain foods tend to be healthier due to their high dietary fiber and phytoconstituents, typically lost during refining.

28 Nov 2022

Cannabis studies receive significant media coverage regardless of the clinical outcome

In cannabis trials against pain, people who take placebos report feeling largely the same level of pain relief as those who consume the active cannabinoid substance.

28 Nov 2022

Study provides first direct evidence of caffeine's ergogenicity on sprint running in athletics

At the international level of sport, even the smallest advantage can take an athlete from being a mere participant to a podium finisher.

28 Nov 2022

New technologies and recent advances in the study of T cells and T-cell epitope discovery in food allergy research

In a recent study, scientists reviewed the latest technological advancements and T cell epitope discovery associated with food allergy.

28 Nov 2022

Novel cancer-fighting nanoparticles co-deliver a chemotherapy drug and immunotherapy

University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, according to a new Nature Nanotechnology study published today.

24 Nov 2022

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after treatment, finds a trial published by The BMJ today.

24 Nov 2022

High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

Patients with high-risk stage III-IV melanoma who received pembrolizumab after their surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon.

23 Nov 2022

Morphine does not reduce worst breathlessness, study finds

Sometimes healthcare professionals treat patients with opioids such as morphine to relieve symptoms, but there has been a lack of evidence as to whether this helps with severe chronic breathlessness.

23 Nov 2022

Vitamin D appears to have no substantial impact on statin-related muscle pain

Patients who take statins to lower high cholesterol levels often complain of muscle pains, which can lead them to stop taking the highly effective medication and put them at greater risk of heart attack or stroke.

23 Nov 2022

The safety and immunogenicity of a fourth dose of NVX-CoV2373

Researchers assessed the immunogenicity and safety of a fourth homologous boost dose of a recombinant SARS-CoV-2 spike protein vaccine called NVX-CoV2373.

23 Nov 2022

Approved and developing passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

Researchers explored active and passive vaccination among children against respiratory syncytial virus (RSV).

22 Nov 2022

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the renin-angiotensin system on the clinical outcomes of individuals with coronavirus disease 2019 (COVID-19).

21 Nov 2022

Does influenza vaccination reduce death and vascular events in patients with heart failure?

Researchers conducted a placebo-controlled, double-blind clinical trial to assess whether influenza vaccination effectively reduced vascular events and mortality among patients with heart failure.

21 Nov 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

Marijuana and e-cigarettes both increase risks of cardiac arrhythmias

In a recent study published in the Heart Rhythm journal, researchers at the University of California, San Francisco, assessed the relationship between different types of inhaled marijuana or tobacco product usage with ventricular and atrial arrhythmias.

17 Nov 2022

What is the prevalence of contraindications to Paxlovid among hospitalized COVID-19 patients?

Researchers examined the prevalence of contraindications to nirmatrelvir-ritonavir (Paxlovid) in hospitalized coronavirus disease 2019 (COVID-19) patients.

17 Nov 2022

PALS program effective in ensuring diverse representation in lupus clinical trials

The Lupus Research Alliance and its affiliate Lupus Therapeutics presented data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus Studies (PALS), in increasing knowledge, perception, and willingness among people with Systemic Lupus Erythematosus (SLE) to participate in clinical trials.

14 Nov 2022

Oral deucravacitinib shows promise in patients with active lupus

Tyrosine kinases are enzymes that play central roles in signaling by cytokines involved in the pathogenesis of autoimmune diseases, including lupus.

14 Nov 2022

Placebo News and Research

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

Study examines cannabidiol's effect on simulated driving

How does quinoa affect the gut microbiome of men?

Cannabis studies receive significant media coverage regardless of the clinical outcome

Study provides first direct evidence of caffeine's ergogenicity on sprint running in athletics

New technologies and recent advances in the study of T cells and T-cell epitope discovery in food allergy research

Novel cancer-fighting nanoparticles co-deliver a chemotherapy drug and immunotherapy

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

Morphine does not reduce worst breathlessness, study finds

Vitamin D appears to have no substantial impact on statin-related muscle pain

The safety and immunogenicity of a fourth dose of NVX-CoV2373

Approved and developing passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

Does influenza vaccination reduce death and vascular events in patients with heart failure?

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

Marijuana and e-cigarettes both increase risks of cardiac arrhythmias

What is the prevalence of contraindications to Paxlovid among hospitalized COVID-19 patients?

PALS program effective in ensuring diverse representation in lupus clinical trials

Oral deucravacitinib shows promise in patients with active lupus

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News